Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Senior who wrote (57787)	8/25/2016 11:41:38 AM
From: gcrispin	Read Replies (1) of 78751

I added to my AGN position this morning. I consider it a GARP stock. Below is a portion of the latest Morningstar analysis. Given its expected share repurchases, we see a relatively straightforward path for Allergan to achieve $20 in adjusted earnings per share by 2018. With over $20 billion in cash remaining following recent debt prepayment and anticipated share repurchases under its $10 billion authorization, we anticipate management will continue to make prudent investments in its core therapeutic segments, particularly in its widest moat areas of aesthetics and ophthalmology.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next